Physician profile
Michael A Blair
NPI 1104949841
$43,357.25
in general payments reported to CMS, 2019-2025
24 companies · $8,445 in 2025
The $8,445 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,254 · 2020: $1,757 · 2021: $7,791 · 2022: $4,600 · 2023: $8,631 · 2024: $5,879 · 2025: $8,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,900.00 |
| Food and Beverage | $2,054.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $23,405.20 | 2019-2025 | Clareon, Clareon Panoptix Pro, Ngenuity |
| Alcon Research LLC | $17,891.89 | 2019-2025 | |
| Abbvie INC. | $573.17 | 2022-2025 | Durysta, Lumigan, Vuity |
| Biotissue Holdings INC. | $325.56 | 2021-2025 | |
| Sight Sciences, INC. | $199.92 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $141.52 | 2019-2023 | |
| Allergan, INC. | $137.39 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $109.80 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $106.89 | 2019-2024 | Tecnis Simplicity, Complera |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.64 | 2019-2020 | |
| Ocular Therapeutix, INC. | $58.22 | 2021-2023 | Dextenza |
| Glaukos Corporation | $53.28 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $47.78 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $34.51 | 2019-2020 | |
| Shire North American Group INC | $33.23 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.12 | 2022 | |
| Dompe US, INC. | $23.19 | 2025 | Oxervate |
| Optinose US, INC. | $20.29 | 2022 | |
| Omeros Corporation | $19.52 | 2021 | |
| Oyster Point Pharma, INC. | $19.24 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.62 | 2021 | |
| Eyepoint US, INC. | $18.13 | 2019 | |
| Ivantis, INC | $17.34 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.